[New treatments for idiopathic juvenile arthritis]

B Bader-Meunier; P Quartier

doi:10.1016/j.arcped.2009.07.020

[New treatments for idiopathic juvenile arthritis]

Arch Pediatr. 2009 Dec;16(12):1607-11. doi: 10.1016/j.arcped.2009.07.020. Epub 2009 Nov 5.

[Article in French]

Authors

B Bader-Meunier¹, P Quartier

Affiliation

¹ Service d'Immunologie, d'Hématologie et de Rhumatologie Pédiatriques, Centre de Référence << Arthrites Juvéniles >>, Université Paris Descartes, Hôpital Necker-Enfants-Malades, 149 Rue de Sèvres, 75015 Paris, France. brigitte.bader-meunier@nck.aphp.fr

PMID: 19896351
DOI: 10.1016/j.arcped.2009.07.020

Abstract

Immunosuppressants, including methotrexate and more recently anti-TNF alpha, anti-IL1 and anti-IL6 receptor, have modified the prognosis of juvenile idiopathic arthritis. Growth hormone was shown to limit growth retardation due to general corticotherapy.

Publication types

English Abstract

MeSH terms

Adolescent
Antirheumatic Agents / therapeutic use
Arthritis, Juvenile / drug therapy*
Drug Therapy, Combination
Humans
Immunosuppressive Agents / therapeutic use
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Interleukin-6 / antagonists & inhibitors
Prognosis
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Antirheumatic Agents
Immunosuppressive Agents
Interleukin 1 Receptor Antagonist Protein
Interleukin-6
Tumor Necrosis Factor-alpha